The surge in cases is closely tied to seasonal weather patterns—intermittent rains, fluctuating temperatures, and high ...

chloramphenicol ophthalmic ointment and solution, erythromycin ophthalmic ointment, Quixin® ophthalmic solution (levofloxacin), Chibroxin® ophthalmic solution (norfloxacin) and Ilotycin ...

Development of novel therapies targeting different pathogenic mechanisms is sought-after. The aim of this study is to evaluate safety and efficacy of recombinant human nerve growth factor (rhNGF) eye ...

Dust storms can pose risks to your eyes, causing a range of problems from mild irritation to serious vision-threatening ...

From using dirty hands to apply eye drops to using them without doctor prescription, know the common mistakes that people ...

The global ophthalmic eye drop market is expected to grow from USD 17,271.8 million in 2024 to USD 25,876.4 million by 2034. By 2034, the market is projected to surge at 4.7% CAGR. The ophthalmic eye ...

Perhaps a too-fast flow of drops from the moxifloxacin bottle was ... Resistance is increasing to many ophthalmic antibiotics, including sulfacetamide, penicillins, and some third-generation ...

Blink Nourish is the first and only vitamin-enriched preservative-free eye drop designed to replenish and rebalance the tear film. Enriched with vitamin B12, which gives the drops its rosy color ...

The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic solution) for the treatment of signs and symptoms of dry eye disease.

Currently, dry eye disease treatment options are limited due to slow therapeutic onset, patient dissatisfaction, and poor adherence. Tryptyr works by stimulating corneal sensory nerves to rapidly ...

MONDAY, June 2, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved the first-in-class TRPM8 receptor agonist Tryptyr (acoltremon ophthalmic solution) for the treatment of ...